No Data
Merus Rises 10% Following Updated Phase 2 Data on Petosemtamab for Head and Neck Cancer
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
XPeng, NovoCure, Merus, Gap And Other Big Stocks Moving Higher On Monday
LifeSci Capital Maintains Merus(MRUS.US) With Buy Rating, Maintains Target Price $100
TD Cowen Maintains Merus(MRUS.US) With Buy Rating
Merus Shares Are Trading Higher After the Company Announced It Entered Into an Agreement to Exclusively License the Right to Ptx the Right to Commercialize Zenocutuzumab (Zeno) for Nrg1 Fusion-positive Cancer in the US.
No Data
No Data
